RE: Trinity12 Apr 2022 14:48
Ruck, I wasn’t questioning your figures, I’m quoting the industry standard risk adjusted NPV that trinity used.
From what I can see, they are valuing the company as if it’s current trials were still in the ore clinical phase.
Although there valuation for scancell is somewhat 40% higher than today it is still considerably undervalued by industry standard raNPV